Cogent Biosciences, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Cogent Biosciences, Inc. (COGT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 37.16 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-10
- Cogent Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 37.78M shares, a 27.89% increase year-over-year.
- Cogent Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 29.54M shares, a 31.84% increase year-over-year.
- Cogent Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 22.40M shares, a 35.56% decline year-over-year.
- Cogent Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 34.77M shares, a 3.25% decline year-over-year.
- Cogent Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 37.00M shares, a 52.34% increase from fiscal 2024.
- Cogent Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 24.29M shares, a 34.93% increase from fiscal 2023.
- Cogent Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 18.00M shares, a 40.30% increase from fiscal 2022.
- Cogent Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 12.83M shares, a 62.93% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 37.16M shares 10-Q · filed 2026-08-10 | |||||||
| 2026-03-31 | 37.78M shares 10-Q · filed 2026-05-05 | |||||||
| 2025-12-31 | 37.00M shares 10-K · filed 2026-02-17 | |||||||
| 2025-09-30 | 30.55M shares 10-Q · filed 2025-11-07 | |||||||
| 2025-06-30 | 30.24M shares 10-Q · filed 2026-08-10 | |||||||
| 2025-03-31 | 29.54M shares 10-Q · filed 2026-05-05 | |||||||
| 2024-12-31 | 24.29M shares 10-K · filed 2026-02-17 | |||||||
| 2024-09-30 | 24.02M shares 10-Q · filed 2025-11-07 | 48.50M shares 10-Q · filed 2024-11-12 | ||||||
| 2024-06-30 | 23.63M shares 10-Q · filed 2025-08-05 | 49.11M shares 10-Q · filed 2024-08-06 | ||||||
| 2024-03-31 | 22.40M shares 10-Q · filed 2025-05-06 | 41.02M shares 10-Q · filed 2024-05-07 | ||||||
| 2023-12-31 | 18.00M shares 10-K · filed 2026-02-17 | 36.62M shares 10-K · filed 2024-02-26 | ||||||
| 2023-09-30 | 36.64M shares 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | 37.53M shares 10-Q · filed 2024-08-06 | |||||||
| 2023-03-31 | 34.77M shares 10-Q · filed 2024-05-07 | |||||||
| 2022-12-31 | 12.83M shares 10-K · filed 2025-02-25 | 33.09M shares 10-K · filed 2023-03-14 | ||||||
| 2022-09-30 | 33.98M shares 10-Q · filed 2023-11-07 | 32.73M shares 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | 34.35M shares 10-Q · filed 2023-08-08 | |||||||
| 2022-03-31 | 35.93M shares 10-Q · filed 2023-05-09 | |||||||
| 2021-12-31 | 34.62M shares 10-K · filed 2024-02-26 | |||||||
| 2021-09-30 | 33.98M shares 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | 33.57M shares 10-Q · filed 2022-08-09 | |||||||
| 2021-03-31 | 32.61M shares 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | 36.31M shares 10-K · filed 2022-03-15 | |||||||
| 2020-09-30 | 41.50M shares 10-Q · filed 2021-11-10 | |||||||
| 2020-06-30 | 869.43K shares 10-Q · filed 2021-08-16 | 3.48M shares 10-Q · filed 2020-08-11 | ||||||
| 2020-03-31 | 1.03M shares 10-Q · filed 2021-05-12 | 4.46M shares 10-Q · filed 2020-05-11 | ||||||
| 2019-12-31 | 1.26M shares 10-K · filed 2021-03-16 | 5.04M shares 10-K · filed 2020-03-26 | ||||||
| 2019-09-30 | 1.17M shares 10-Q · filed 2020-11-09 | 4.66M shares 10-Q · filed 2019-11-12 | ||||||
| 2019-06-30 | 4.69M shares 10-Q · filed 2020-08-11 | |||||||
| 2019-03-31 | 4.27M shares 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | 3.66M shares 10-K · filed 2020-03-26 | |||||||
| 2018-09-30 | 3.77M shares 10-Q · filed 2019-11-12 | |||||||
| 2018-06-30 | 3.83M shares 10-Q · filed 2019-08-12 | |||||||
| 2018-03-31 | 17.10M shares 10-Q · filed 2019-05-13 | |||||||
| 2017-12-31 | 16.39M shares 10-K · filed 2019-03-28 | |||||||
| 2017-09-30 | 15.92M shares 10-Q · filed 2018-11-13 | |||||||
| 2017-06-30 | 15.78M shares 10-Q · filed 2018-08-13 | |||||||
| 2017-03-31 | 15.78M shares 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |